Merck Serono resubmits Cladribine Tablets in the US
This article was originally published in Scrip
Executive Summary
Merck Serono has refiled the NDA for its oral relapsing-remitting multiple sclerosis (RRMS) therapy Cladribine Tablets (cladribine) in the US following the refusal to file letter it received in November (scripnews.com, 1 December 2009).